CABONEN - A Phase II Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
Latest Information Update: 30 Sep 2024
Price :
$35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Neuroendocrine carcinoma; Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms CABONEN
- 13 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 14 Jun 2023 Planned End Date changed from 30 Jun 2023 to 31 Oct 2024.
- 14 Jun 2023 Planned primary completion date changed from 31 May 2023 to 30 Sep 2024.